Patents by Inventor Qui-Lim Choo
Qui-Lim Choo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11931417Abstract: Methods are provided for producing a PEGylated interleukin 11 (IL-11) by treating a recombinant IL-11 PEGylated with an equimolar to low molar excess of PEG carrying an amine-reactive group to achieve a highly pure monoconjugate preparation, which provides improved half-life in serum while having desirable therapeutic activity and presenting fewer side-effects. Most preferably, the IL-11 is an N-terminally truncated human or humanized IL-11 and has a 20 Kd or 40 Kd branched PEG moiety, Y- or comb-shaped in particular, coupled to the N-terminal amino group. Such compounds are characterized by substantially increased stability in serum and sustained biological activity while exhibiting significantly reduced plasma expansion.Type: GrantFiled: February 11, 2021Date of Patent: March 19, 2024Assignee: Nansha Biologics (Hong Kong) LimitedInventors: Kuo-Ming Yu, Qui-Lim Choo, Manson Fok, Johnson Yiu-Nam Lau
-
Patent number: 11898180Abstract: Compositions and methods for the preparation of high purity arginase and high efficiency preparation of monosubstituted polyethylene glycol conjugation of arginase are provided, as are methods for using arginase in combination with asparaginase to inhibit cancer cells. High purity arginase is provided by applying an initial high temperature precipitation step, followed by ion exchange to provide arginase at a purity of 90% or greater. Conjugation with either linear or branched polyethylene glycol is performed using a maleimide-derivatized polyethylene glycol at low molar excess relative to arginase and at reduced temperature. Such polyethylene glycol-derivatized arginase is useful in combination with asparaginase in inhibiting the growth of cancer cells, particularly cells that have low endogenous asparaginase expression.Type: GrantFiled: August 16, 2018Date of Patent: February 13, 2024Assignee: Avalon Polytom (HK) LimitedInventors: Johnson Yiu-Nam Lau, Yun Chung Leung, Kuo-Ming Yu, Yuk-Keung Yeung, Pui Shi Pang, Qui-Lim Choo
-
Patent number: 11629367Abstract: Recombinant interleukin-11 (rhIL-11) is expressed in yeast, then isolated from aerobic fermentation media by precipitation, solubilization of the precipitate in the presence of a denaturant, and renaturation of the solubilized protein. Renatured rhIL-11 is further purified by cation exchange and hydrophobic interaction chromatography to provide a highly purified rhIL-11 with high biological activity and low rhIL-11 dimer and oxidized rhIL-11 content.Type: GrantFiled: January 15, 2018Date of Patent: April 18, 2023Assignee: Nansha Biologies (HK) LimitedInventors: Qui-Lim Choo, Manson Fok, Johnson Yiu-Nam Lau
-
Publication number: 20210317500Abstract: Recombinant IL-11 is expressed in yeast, then isolated from aerobic fermentation media by precipitation, solubilization of the precipitate in the presence of a denaturant, and renaturation of the solubilized protein. Renatured rhIL-11 is further purified by cation exchange and hydrophobic interaction chromatography to provide a highly purified rhIL-11 with high biological activity and low rhIL-11 dimer and oxidized rhIL-11 content.Type: ApplicationFiled: January 15, 2018Publication date: October 14, 2021Inventors: Qui-Lim CHOO, Manson FOK, Johnson Yiu-Nam LAU
-
Publication number: 20210268117Abstract: Methods are provided for producing a PEGylated interleukin 11 (IL-11) tby treating a recombinant IL-11 PEGylated with an equimolar to low molar excess of PEG carrying an amine-reactive group to achieve a highly pure monoconjugate preparation, which provides improved half-life in serum while having desirable therapeutic activity and presenting fewer side-effects. Most preferably, the IL-11 is an N-terminally truncated human or humanized IL-11 and has a 20 Kd or 40 Kd branched PEG moiety, Y- or comb-shaped in particular, coupled to the N-terminal amino group. Such compounds are characterized by substantially increased stability in serum and sustained biological activity while exhibiting significantly reduced plasma expansion.Type: ApplicationFiled: February 11, 2021Publication date: September 2, 2021Inventors: Kuo-Ming YU, Qui-Lim CHOO, Manson FOK, Johnson Yiu-Nam LAU
-
Publication number: 20210189370Abstract: Compositions and methods for the preparation of high purity arginase and high efficiency preparation of monosubstituted polyethylene glycol conjugation of arginase are provided, as are methods for using arginase in combination with asparaginase to inhibit cancer cells. High purity arginase is provided by applying an initial high temperature precipitation step, followed by ion exchange to provide arginase at a purity of 90% or greater. Conjugation with either linear or branched polyethylene glycol is performed using a maleimide-derivatized polyethylene glycol at low molar excess relative to arginase and at reduced temperature. Such polyethylene glycol-derivatized arginase is useful in combination with asparaginase in inhibiting the growth of cancer cells, particularly cells that have low endogenous asparaginase expression.Type: ApplicationFiled: August 16, 2018Publication date: June 24, 2021Inventors: Johnson Yiu-Nam LAU, Yun Chung LEUNG, Wai Hung LO, Kuo-Ming YU, Yuk-Keung YEUNG, Pui Shi PANG, Qui-Lim CHOO
-
Patent number: 10946103Abstract: Methods are provided for treating an individual with a pharmaceutical preparation that includes a recombinant IL-11 PEGylated at equimolar to low molar excess of PEG to achieve a highly pure monoconjugate preparation, which provides improved half-life in serum while having desirable therapeutic activity and presenting fewer side-effects. Most preferably, the IL-11 is an N-terminally truncated human or humanized IL-11 and has a 20 Kd or 40 Kd branched PEG moiety, Y- or comb-shaped in particular, coupled to the N-terminal amino group. Such compounds are characterized by substantially increased stability in serum and sustained biological activity while exhibiting significantly reduced plasma expansion.Type: GrantFiled: May 21, 2019Date of Patent: March 16, 2021Assignee: Nansha Biologics (Hong Kong) LimitedInventors: Kuo-Ming Yu, Qui-Lim Choo, Manson Fok, Johnson Yiu-Nam Lau
-
Patent number: 10881739Abstract: Compositions are presented that include a recombinant IL-11 PEGylated at equimolar to low molar excess of PEG to achieve a highly pure monoconjugate preparation, which provides improved half-life in serum while having desirable therapeutic activity and presenting fewer side-effects. Most preferably, the IL-11 is an N-terminally truncated human or humanized IL-11 and has a 20 Kd or 40 Kd branched PEG moiety, Y- or comb-shaped in particular, coupled to the N-terminal amino group. Such compounds are characterized by substantially increased stability in serum and sustained biological activity while exhibiting significantly reduced plasma expansion.Type: GrantFiled: May 21, 2019Date of Patent: January 5, 2021Assignee: Nansha Biologies (Hong Kong) LimitedInventors: Kuo-Ming Yu, Qui-Lim Choo, Manson Fok, Johnson Yiu-Nam Lau
-
Publication number: 20190365908Abstract: Compositions are presented that include a recombinant IL-11 PEGylated at equimolar to low molar excess of PEG to achieve a highly pure monoconjugate preparation, which provides improved half-life in serum while having desirable therapeutic activity and presenting fewer side-effects. Most preferably, the IL-11 is an N-terminally truncated human or humanized IL-11 and has a 20 Kd or 40 Kd branched PEG moiety, Y- or comb-shaped in particular, coupled to the N-terminal amino group. Such compounds are characterized by substantially increased stability in serum and sustained biological activity while exhibiting significantly reduced plasma expansion.Type: ApplicationFiled: May 21, 2019Publication date: December 5, 2019Inventors: Kuo-Ming Yu, Qui-Lim Choo, Manson Fok, Johnson Yiu-Nam Lau
-
Publication number: 20190365909Abstract: Methods are provided for treating an individual with a pharmaceutical preparation that includes a recombinant IL-11 PEGylated at equimolar to low molar excess of PEG to achieve a highly pure monoconjugate preparation, which provides improved half-life in serum while having desirable therapeutic activity and presenting fewer side-effects. Most preferably, the IL-11 is an N-terminally truncated human or humanized IL-11 and has a 20 Kd or 40 Kd branched PEG moiety, Y- or comb-shaped in particular, coupled to the N-terminal amino group. Such compounds are characterized by substantially increased stability in serum and sustained biological activity while exhibiting significantly reduced plasma expansion.Type: ApplicationFiled: May 21, 2019Publication date: December 5, 2019Inventors: Kuo-Ming YU, Qui-Lim CHOO, Manson FOK, Johnson Yiu-Nam LAU
-
Patent number: 10335492Abstract: Compositions and methods are presented in which recombinant IL-11 is PEGylated to achieve improved half-life in serum while having desirable therapeutic activity and presenting less side-effects. Most preferably, the IL-11 is an N-terminally truncated human or humanized IL-11 and has a 20 Kd or 40 Kd branched PEG moiety, Y- or comb-shaped in particular, coupled to the N-terminal amino group. Such compounds are characterized by substantially increased stability in serum and sustained biological activity while exhibiting significantly reduced plasma expansion.Type: GrantFiled: March 1, 2016Date of Patent: July 2, 2019Assignee: NANSHA BIOLOGICS (HONG KONG) LIMITEDInventors: Kuo-Ming Yu, Qui-Lim Choo, Manson Fok, Johnson Yiu-Nam Lau
-
Publication number: 20180036418Abstract: Compositions and methods are presented in which recombinant IL-11 is PEGylated to achieve improved half-life in serum while having desirable therapeutic activity and presenting less side-effects. Most preferably, the IL-11 is an N-terminally truncated human or humanized IL-11 and has a 20 Kd or 40 Kd branched PEG moiety, Y- or comb-shaped in particular, coupled to the N-terminal amino group. Such compounds are characterized by substantially increased stability in serum and sustained biological activity while exhibiting significantly reduced plasma expansion.Type: ApplicationFiled: March 1, 2016Publication date: February 8, 2018Inventors: Kuo-Ming YU, Qui-Lim CHOO, Manson FOK, Johnson Yiu-Nam LAU
-
Patent number: 8481050Abstract: A tissue culture system for production of infectious hepatitis C virus is described. In particular, the invention provides recombinant monocistronic and bicistronic genomic constructs for production of virus, including constructs for production of wild-type HCV type 2a strain JFH1 and constructs for production of chimeric viruses comprising HCV proteins from strain JFH1 and a second HCV isolate. Constructs of the invention also include a reporter gene to facilitate measurement of RNA replication and viral infectivity in cultures. The cell culture system may also include various factors that improve viral replication or infectivity. In addition, a neutralization assay using HCV grown in cell culture is described.Type: GrantFiled: August 22, 2007Date of Patent: July 9, 2013Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Qui-Lim Choo, Jang Han, Michael Houghton, Taewoo Kwon, Hyun Chul Song, Yifei Zhu
-
Patent number: 8475808Abstract: Recombinant production of immunogenic West Nile Virus (WNV) proteins is described. These proteins, heterodimers comprising the proteins, fusions thereof, polynucleotides encoding the proteins, and combinations thereof, as well as antibodies produced therefrom, can be used in immunogenic compositions for preventing, treating and diagnosing WNV infection. Also described are highly sensitive ELISA and strip immunoassay methods for detecting the presence of WNV in biological samples.Type: GrantFiled: May 21, 2004Date of Patent: July 2, 2013Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: William Andrews, David Chien, Qui-Lim Choo, Stephen Coates, Doris Coit, Charles Harrington, Susan Hilt, Michael Houghton, Angelica Medina-Selby, Sergio Pichuantes, Yiu-Lian Fong
-
Publication number: 20110150911Abstract: Immunogenic compositions for use in treating, preventing and diagnosing infection caused by the California (CAL) serotype of the genus Bunyavirus, such as La Crosse virus (LACV), are disclosed. Also described are reagents for use in diagnostic assays.Type: ApplicationFiled: November 19, 2004Publication date: June 23, 2011Inventors: Qui-Lim Choo, Michael Houghton, Elizabeth Scott, Amy Weiner
-
Publication number: 20100227311Abstract: A tissue culture system for production of infectious hepatitis C virus is described. In particular, the invention provides recombinant monocistronic and bicistronic genomic constructs for production of virus, including constructs for production of wild-type HCV type 2a strain JFH1 and constructs for production of chimeric viruses comprising HCV proteins from strain JFH1 and a second HCV isolate. Constructs of the invention also include a reporter gene to facilitate measurement of RNA replication and viral infectivity in cultures. The cell culture system may also include various factors that improve viral replication or infectivity. In addition, a neutralization assay using HCV grown in cell culture is described.Type: ApplicationFiled: August 22, 2007Publication date: September 9, 2010Inventors: Jang Han, Qui-Lim Choo, Michael Houghton, Taewoo Kwon, Hyun Chul Song, Yifei Zhu
-
Patent number: 7790366Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBH), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicates that HCV may be related to the Flaviviruses. The HCV cDNA sequences and the polypeptides encoded therein are useful as reagents for the detection and therapy of HCV. The reagents provided in the invention are also useful for the isolation of NANBH agent(s), for the propagation of these agents in tissue culture, and for the screening of antiviral agents for HCV.Type: GrantFiled: May 15, 1995Date of Patent: September 7, 2010Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
-
Publication number: 20080318275Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.Type: ApplicationFiled: March 17, 2008Publication date: December 25, 2008Inventors: Robert O. Ralston, Frank Marcus, Kent B. Thudium, Barbara A. Gervase, John A. Hall, Kim M. Berger, Qui-Lim Choo, Michael Houghton, George Kuo
-
Patent number: 7429385Abstract: Methods for obtaining recombinantly produced, C-terminally truncated, E1 and E2 polypeptides from cell lysates are disclosed. The intracellularly expressed truncated molecules display improved biological properties as compared to their secreted counterparts.Type: GrantFiled: February 18, 2003Date of Patent: September 30, 2008Assignee: Novartis Vaccines & DiagnosticsInventors: Michael Houghton, Qui-Lim Choo, Sergio Abrignani, David Chien, Mark Selby, Edward Glazer
-
Publication number: 20070092538Abstract: Recombinant production of immunogenic West Nile Virus (WNV) proteins is described. These proteins, heterodimers comprising the proteins, fusions thereof, polynucleotides encoding the proteins, and combinations thereof, as well as antibodies produced therefrom, can be used in immunogenic compositions for preventing, treating and diagnosing WNV infection. Also described are highly sensitive ELISA and strip immunoassay methods for detecting the presence of WNV in biological samples.Type: ApplicationFiled: May 21, 2004Publication date: April 26, 2007Inventors: William Andrews, David Chien, Qui-Lim Choo, Stephen Coates, Doris Coit, Charles Harrington, Susan Hilt, Michael Houghton, Angelica Medina-Selby, Sergio Pichuantes